A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant-Reference-Cited by-同舟云学术

A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant

Published:2018-06-08 Issue:11 Volume:2 Page:1283-1293
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

French Shauna L.¹,Thalmann Claudia²³,Bray Paul F.⁴,Macdonald Lynn E.⁵,Murphy Andrew J.⁵,Sleeman Mark W.²³,Hamilton Justin R.¹^ORCID

Affiliation:

1. Australian Centre for Blood Diseases,

2. Department of Physiology, and

3. Biomedicine Discovery Institute, Monash University, Melbourne, Australia;

4. Department of Medicine & Program in Molecular Medicine, University of Utah, Salt Lake City, UT; and

5. Regeneron Pharmaceuticals Inc, Tarrytown, NY

Abstract

Key Points A human monoclonal inhibitory PAR4 antibody is equally effective in platelets expressing the Ala120 or hyperreactive Thr120 PAR4 variant. Antibody-mediated PAR4 inhibition is markedly anti-thrombotic in human blood, independent of PAR4 genotype.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/11/1283/881739/advances015552.pdf

Reference27 articles.

1. Protease-activated receptors in hemostasis, thrombosis and vascular biology;Coughlin;J Thromb Haemost,2005

2. Thrombin signalling and protease-activated receptors;Coughlin;Nature,2000

3. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin;Kahn;J Clin Invest,1999

4. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes;Tricoci;N Engl J Med,2012

5. Vorapaxar in the secondary prevention of atherothrombotic events;Morrow;N Engl J Med,2012

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A mouse model of the protease-activated receptor 4 Pro310Leu variant has reduced platelet reactivity;Journal of Thrombosis and Haemostasis;2024-06

2. Protease activated receptor-4: ready to be part of the antithrombosis spectrum;Current Opinion in Hematology;2024-05-30

3. A Mouse Model of the Protease Activated Receptor 4 (PAR4) Pro310Leu Variant has Reduced Platelet Reactivity;2023-12-01

4. Targeting PAR4 to Reduce Atherosclerosis;Arteriosclerosis, Thrombosis, and Vascular Biology;2023-11

5. Novel Strategy to Combat the Procoagulant Phenotype in Heparin-Induced Thrombocytopenia Using 12-LOX Inhibition;Arteriosclerosis, Thrombosis, and Vascular Biology;2023-10